Neuroprotective activity of leukemia inhibitory factor is relayed through myeloid zinc finger-1 in a rat model of stroke
The aim of this study was to determine whether leukemia inhibitory factor (LIF) exerts its neuroprotective effects through signal transduction of the transcription factor myeloid zinc finger-1 (MZF-1). According to the hypothesis of this study, MZF-1 mediates LIF-induced neuroprotective signaling during ELVO through increased expression and transcriptional activity. To determine the in vivo role of MZF-1 in LIF-induced neuroprotection, we used Genomatix software was used to MZF-1 sites in the promoter region of the rat superoxide dismutase 3 (SOD3) gene. Stroke was induced via middle cerebral artery occlusion, and animals were administered PBS or 125 μg/kg LIF at 6, 24, and 48 h after the injury. MZF-1 binding activity was measured using electrophoretic mobility shift assay (EMSA) and its expression/localization were determined using western blot and immunohistochemical analysis. To determine whether MZF-1 relays LIF-induced neuroprotection in vitro, primary cultured neurons were subjected to oxygen-glucose deprivation (OGD) after treatment with PBS or LIF. MZF-1 expression was measured in vitro using real time PCR and immunohistochemical staining. Transfection with siRNA was used to determine whether LIF protected cultured neurons against OGD after silencing MZF-1 expression. Four MZF-1 binding sites were identified by Genomatix, and EMSA confirmed in vivo binding activity in brain after MCAO. LIF significantly increased MZF-1 protein levels compared to PBS treatment at 72 h post-MCAO. In vivo nuclear localization of MZF-1 as well as co-localization of SOD3 and MZF-1 was observed in the cortical neurons of LIF-treated rats. Primary cultured neurons treated with LIF had significantly higher levels of MZF-1 mRNA and protein after LIF treatment compared to neurons treated with PBS. Finally, knockdown MZF-1 using siRNA counteracted the neuroprotective effects of LIF in vitro. These data demonstrate that LIF-mediated neuroprotection is dependent upon MZF-1 activity. Furthermore, these findings identify a novel neuroprotective pathway that employs MZF-1, a transcription factor associated with hematopoietic gene expression.
KeywordsTranscription factors Ischemia Stroke Antioxidants Cytokines Neurosurvival
emergent large vessel occlusion
leukemia inhibitory factor
middle cerebral artery occlusion
myeloid zinc finger-1
neuronal nuclear antigen
superoxide dismutase 3
tissue plasminogen activator
The authors would like to acknowledge Dr. Jerome Breslin at the University of South Florida for the use of his laboratory’s Nucleofector™ device as well as Dr. Chris Katnik for his assistance in the isolation of primary rat neurons.
Funding for the experiments detailed in this paper was provided by the National Institute for Neurological Disorders and Stroke [Grants: 1R21NS078517–01, 1R56NS091146–01, and 1R01NS091146-01].
Compliance with ethical standards
Conflict of interest
- Goyal M, Menon BK, van Zwam WH, Dippel DWJ, Mitchell PJ, Demchuk AM, Dávalos A, Majoie CBLM, van der Lugt A, de Miquel MA, Donnan GA, Roos YBWEM, Bonafe A, Jahan R, Diener H-C, van den Berg LA, Levy EI, Berkhemer OA, Pereira VM, Rempel J, Millán M, Davis SM, Roy D, Thornton J, Román LS, Ribó M, Beumer D, Stouch B, Brown S, Campbell BCV, van Oostenbrugge RJ, Saver JL, Hill MD, Jovin TG (2016) Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 387(10029):1723–1731PubMedCrossRefGoogle Scholar
- Hromas R, Davis B, Rauscher F III, Klemsz M, Tenen D, Hoffman S, Xu D, Morris J (1996b) Hematopoietic transcriptional regulation by the myeloid zinc finger gene, MZF-1. Molecular Aspects of Myeloid Stem Cell Development. Springer, New York, pp 159–164Google Scholar
- Ip NY, Nye SH, Boulton TG, Davis SM, Taga T, Li Y, Birren SJ, Yasukawa K, Kishimoto T, Anderson DJ, Stahl N, Yancopoulos GD (1992) CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130. Cell 69(7):1121–1132PubMedCrossRefGoogle Scholar
- Leonardo CC, Hall AA, Collier LA, Ajmo CTJ, Willing AE, Pennypacker KR (2010) Human umbilical cord blood cell therapy blocks the morphological change and recruitment of CD-11b-expressing isolectin-binding proinflammatory cells after middle cerebral artery occlusion. J Neurosci Res 88(6):1213–1222PubMedPubMedCentralGoogle Scholar
- Madsen TE, Melluzzo S, Wira CR, Magdon-Ismail Z, Day D, Gropen T, Investigators NCC (2017) Minorities, women, and stroke belters left behind in t-PA use despite quality improvement efforts. Stroke 48(suppl_1):A116–A116Google Scholar
- Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B (2018) 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 49(3):e46–e99PubMedCrossRefGoogle Scholar
- Schabitz WR, Kruger C, Pitzer C, Weber D, Laage R, Gassler N, Aronowski J, Mier W, Kirsch F, Dittgen T, Bach A, Sommer C, Schneider A (2007) A neuroprotective function for the hematopoietic protein granulocyte-macrophage colony stimulating factor (GM-CSF). J Cereb Blood Flow Metab 28(1):29–43PubMedCrossRefGoogle Scholar
- Talwalkar A, Uddin, S, N. C. f. H. Statistics (2015) Trends in Emergency Department Visits for Ischemic Stroke and Transient Ischemic Attack: United States, 201–2011, US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health StatisticsGoogle Scholar